JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.02187-07v1
82/4/1860    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Moore, P. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, P. L.
Journal of Virology, February 2008, p. 1860-1869, Vol. 82, No. 4
0022-538X/08/$08.00+0     doi:10.1128/JVI.02187-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection{triangledown}

Penny L. Moore,1,{dagger} Elin S. Gray,1,{dagger} Isaac A. Choge,1 Nthabeleng Ranchobe,1 Koleka Mlisana,2 Salim S. Abdool Karim,2 Carolyn Williamson,3 Lynn Morris,1* and the CAPRISA 002 Study Team

AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa,1 Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa,2 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa3

Received 5 October 2007/ Accepted 19 November 2007

The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) subtype C infections is often characterized by high titers, but the response is type specific with little to no cross-neutralizing activity. The specificities of these early neutralizing antibodies are not known; however, the type specificity suggests that they may target the variable regions of the envelope. Here, we show that cross-reactive anti-V3 antibodies developed within 3 to 12 weeks in six individuals but did not mediate autologous neutralization. Using a series of chimeric viruses, we found that antibodies directed at the V1V2, V4, and V5 regions contributed to autologous neutralization in some individuals, with V1V2 playing a more substantial role. However, these antibodies did not account for the total neutralizing capacity of these sera against the early autologous virus. Antibodies directed against the C3-V4 region were involved in autologous neutralization in all four sera studied. In two sera, transfer of the C3-V4 region rendered the chimera as sensitive to antibody neutralization as the parental virus. Although the C3 region, which contains the highly variable {alpha}2-helix was not a direct target in most cases, it contributed to the formation of neutralization epitopes as substitution of this region resulted in neutralization resistance. These data suggest that the C3 and V4 regions combine to form important structural motifs and that epitopes in this region are major targets of the early autologous neutralizing response in HIV-1 subtype C infection.


* Corresponding author. Mailing address: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa. Phone: 2711 386 6332. Fax: 2711 386 6453. E-mail: lynnm{at}nicd.ac.za

{triangledown} Published ahead of print on 5 December 2007.

{dagger} P.L.M. and E.S.G. contributed equally to this work.


Journal of Virology, February 2008, p. 1860-1869, Vol. 82, No. 4
0022-538X/08/$08.00+0     doi:10.1128/JVI.02187-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.